Biocon's Pertuzumab Approved in EU, Setting a New Benchmark for Biosimilars

Biocon's Pertuzumab Biosimilar Approved in the EU



In a significant advancement for cancer treatment, Biocon Limited has announced that its Pertuzumab biosimilar, marketed as Pebrilzo®, has received marketing authorization from the European Commission (EC). This approval is particularly noteworthy as it represents the first biosimilar granted authorization under the EMA's new streamlined clinical approach. This milestone decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026, underscoring the biosimilar's potential to address the growing need for effective therapies in oncology.

Expanding Treatment Options for HER2-Positive Breast Cancer



Pertuzumab is a critical therapeutic option for patients suffering from HER2-positive breast cancer, a particularly aggressive form of the disease. It works by binding to the HER2 receptor, inhibiting the growth and multiplication of cancer cells that overexpress this receptor. The approval of this biosimilar not only provides an additional treatment avenue for breast cancer patients in the EU but also aims to create a more sustainable healthcare system by offering affordable alternatives to costly biologics.

Shreehas Tambe, CEO of Biocon, expressed his enthusiasm about the approval, stating, "This is a landmark achievement for Biocon, reinforcing our commitment to improving accessibility to essential treatments for patients with HER2-positive breast cancer. The approval of Pebrilzo® marks our fifth oncology biosimilar product authorized in both Europe and the United States, which strengthens our growing oncology portfolio and commitment to meet evolving patient needs."

Focus on Quality and Safety



Biocon's Pertuzumab biosimilar, provided in a 420-mg concentrate for solution preparation, meets stringent EMA standards thanks to comprehensive structural and functional analyses demonstrating high similarity to the reference product. Extensive clinical pharmacokinetic data substantiates that its quality, efficacy, and safety are comparable to that of the original biologic drug, ensuring that patients receive beneficial outcomes through its use.

The biosimilar is indicated for use in combination with trastuzumab and chemotherapy in various therapeutic settings, including neoadjuvant treatment for locally advanced or inflammatory breast cancer, as well as in early-stage breast cancer with a high risk of recurrence. Additionally, it is indicated for patients with metastatic HER2-positive breast cancer who have not previously received anti-HER2 therapy or chemotherapy.

Biocon's Commitment to Oncology



Biocon is steadfast in its mission to expand access to innovative treatments in oncology. Its comprehensive portfolio now includes therapies targeting solid tumors such as breast cancer, palliation for chemotherapy-induced neutropenia, and treatments for conditions associated with advanced cancers. The introduction of the Pertuzumab biosimilar marks an important addition, enhancing the arsenal available to clinicians and patients alike.

Breast cancer remains the most diagnosed cancer among women throughout Europe. According to the European Cancer Information System (ECIS), it constitutes the largest cancer burden, with approximately 15-20% of invasive cases characterized by HER2 overexpression. This underscores the urgent need for sustainable and accessible treatment options within European healthcare systems, reflecting the increasing demand for effective cancer therapies.

About Biocon Limited



Founded in Bengaluru, India, Biocon Limited is a global biopharmaceutical leader focused on providing affordable and life-enhancing medications to patients worldwide. The company is dedicated to addressing significant healthcare challenges, particularly in chronic and non-communicable diseases, through its offerings of both biosimilars and generics. With a robust R&D pipeline, including over 20 biosimilar projects, Biocon continuously strives to meet unmet medical needs in vital therapeutic areas such as oncology, diabetes, cardiovascular diseases, and immunology.

Biocon operates in over 120 countries, supported by a diverse workforce of more than 9,500 employees and a state-of-the-art manufacturing network. The company has consistently been recognized for its commitment to quality, sustainability, and responsible growth. For more information, visit Biocon's official website and follow them on LinkedIn.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.